Abingdon Health Plc (ABDX)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 9.000 |
|---|---|
| 52-week range | 5.500 – 13.000 |
| Return, 1 month / 3 months | −14.3% / −8.6% |
| Return, 1 year / 3 years | +44.0% / −12.2% |
| Trend | Below its 200-day average |
| RSI (14) | 14 |
| Volatility (1 year) | 57.1% |
| Worst drawdown (1 year) | -29.4% |
| Average daily value traded | 1.52M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Abingdon Health is a diagnostics company based in York, England, that develops and manufactures rapid tests using lateral flow technology. It makes test devices for infectious disease and other health conditions, and it provides contract development and manufacturing services to other organisations that need diagnostic tests produced. Its customers include healthcare companies and public health bodies that use or distribute these tests. The company works across the development, regulatory support and manufacture of rapid diagnostic products for markets in the United Kingdom and abroad.
The shares are listed on the London Stock Exchange in UK under the code ABDX, and the price on this page is in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Abingdon Health Plc (ABDX) trades on the London Stock Exchange in UK. It last closed at GBX 9.000 on 27 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,199 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 44.0% and over the last three months it fell 8.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.8% | ||
| From 52-week high | -29.4% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -8.6% | ||
| 6-month return | -5.3% | ||
| 12-month return, skipping the last month | 68.0% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 57.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.4% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.52M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −14.3% |
| 3 months | −8.6% |
| 6 months | −5.3% |
| 1 year | +44.0% |
| 3 years | −12.2% |
| 5 years | −79.5% |
Signals
| 50-day / 200-day average | 10.390 / 9.454 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.898 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.